2/27
07:00 am
ions
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
Low
Report
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
2/27
03:58 am
ions
Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/27
12:00 am
ions
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90 [Yahoo! Finance]
Low
Report
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90 [Yahoo! Finance]
2/26
09:55 am
ions
Ionis Pharmaceuticals (IONS) had its price target raised by Stifel Nicolaus from $73.00 to $77.00. They now have a "hold" rating on the stock.
Low
Report
Ionis Pharmaceuticals (IONS) had its price target raised by Stifel Nicolaus from $73.00 to $77.00. They now have a "hold" rating on the stock.
2/26
07:00 am
ions
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
Low
Report
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
2/25
07:05 pm
ions
Ionis Pharmaceuticals (IONS) was given a new $95.00 price target by Morgan Stanley. They now have an "overweight" rating on the stock.
Low
Report
Ionis Pharmaceuticals (IONS) was given a new $95.00 price target by Morgan Stanley. They now have an "overweight" rating on the stock.
2/25
04:27 pm
ions
Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
2/25
03:58 pm
ions
Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by Needham & Company LLC.
Low
Report
Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by Needham & Company LLC.
2/25
03:58 pm
ions
Ionis Pharmaceuticals (IONS) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Low
Report
Ionis Pharmaceuticals (IONS) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
2/25
02:51 pm
ions
Ionis Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/25
07:24 am
ions
Ionis Pharmaceuticals: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals: Q4 Earnings Snapshot [Yahoo! Finance]
2/25
07:17 am
ions
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs [Yahoo! Finance]
Low
Report
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs [Yahoo! Finance]
2/25
07:00 am
ions
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
Medium
Report
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
2/20
09:21 pm
ions
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS [Yahoo! Finance]
Low
Report
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS [Yahoo! Finance]
2/19
07:05 am
ions
Ionis to present at upcoming investor conferences
Low
Report
Ionis to present at upcoming investor conferences
2/17
02:58 pm
ions
Ionis updates time for fourth quarter and full year 2025 financial results webcast
Low
Report
Ionis updates time for fourth quarter and full year 2025 financial results webcast
2/11
07:21 pm
ions
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release [Yahoo! Finance]
2/11
07:05 am
ions
Ionis to hold fourth quarter and full year 2025 financial results webcast
Low
Report
Ionis to hold fourth quarter and full year 2025 financial results webcast
2/6
07:07 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/30
06:01 am
ions
This 11-year-old has battled a rare disease for years — a breakthrough drug helped deliver relief [CNBC]
Low
Report
This 11-year-old has battled a rare disease for years — a breakthrough drug helped deliver relief [CNBC]
1/28
08:03 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $95.00 price target on the stock.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $95.00 price target on the stock.
1/24
05:09 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
07:00 am
ions
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
Low
Report
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
1/13
02:41 pm
ions
Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return [Yahoo! Finance]
Low
Report
Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return [Yahoo! Finance]
1/12
07:00 am
ions
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
Low
Report
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts